ADC Therapeutics SA Revenue from Contract with Customer, Excluding Assessed Tax
ADC Therapeutics SA (ADCT) reported Revenue from Contract with Customer, Excluding Assessed Tax of $18.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- ADC Therapeutics SA revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $18.63M, a 3.04% increase year-over-year.
- ADC Therapeutics SA revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $20.03M, a 15.11% increase year-over-year.
- ADC Therapeutics SA revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $15.75M, a 12.58% decline year-over-year.
- ADC Therapeutics SA revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $18.09M, a 6.19% increase year-over-year.
- ADC Therapeutics SA revenue from contract with customer, excluding assessed tax for fiscal 2023 was $69.06M, a 7.81% decline from fiscal 2022.
- ADC Therapeutics SA revenue from contract with customer, excluding assessed tax for fiscal 2022 was $74.91M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.63M 10-Q · filed 2026-08-13 | $38.67M 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $20.03M 10-Q · filed 2026-05-04 | |||
| 2025-09-30 | $15.75M 10-Q · filed 2025-11-10 | $33.84M derived: sum of 2 quarters · filed 2026-08-13 | $51.24M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $18.09M 10-Q · filed 2026-08-13 | $35.49M 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $17.40M 10-Q · filed 2026-05-04 | |||
| 2024-09-30 | $18.02M 10-Q · filed 2025-11-10 | $35.05M derived: sum of 2 quarters · filed 2025-11-10 | $52.89M 10-Q · filed 2025-11-10 | $69.54M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $17.03M 10-Q · filed 2025-08-12 | $34.88M 10-Q · filed 2025-08-12 | $51.52M derived: sum of 3 quarters · filed 2025-08-12 | $65.79M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $17.85M 10-Q · filed 2025-05-14 | $34.49M derived: sum of 2 quarters · filed 2025-05-14 | $48.76M derived: sum of 3 quarters · filed 2025-05-14 | $67.95M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $16.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $30.91M derived: sum of 2 quarters · filed 2024-11-07 | $50.11M derived: sum of 3 quarters · filed 2024-11-07 | $69.06M 10-K · filed 2024-03-13 |
| 2023-09-30 | $14.27M 10-Q · filed 2024-11-07 | $33.46M derived: sum of 2 quarters · filed 2024-11-07 | $52.42M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $19.20M 10-Q · filed 2024-08-06 | $38.15M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $18.95M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $74.91M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |